<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04272606</url>
  </required_header>
  <id_info>
    <org_study_id>201912099</org_study_id>
    <nct_id>NCT04272606</nct_id>
  </id_info>
  <brief_title>TXA in Spinal Fusion</brief_title>
  <official_title>Randomized Clinical Trial for Tranexamic Acid (TXA) in Lumbar Interbody Spinal Fusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Zanaty</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic acid and placebo will be given during surgery to patients who have elected to
      undergo lumber interbody fusion on 2 or more levels. Information regarding blood loss,
      transfusions needed, and duration of hospital stay will be collected.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to assess whether tranexamic acid (a drug that is used to coagulate the blood
      and reduce bleeding) use in lumbar spinal fusion can reduce blood loss compared to placebo.
      Thusly reducing need for transfusion, shorting the hospital stay and improving outcomes. For
      this the study will randomize patients who are receiving elective lumbar interbody fusion
      (PLIF or TLIF) of 2 or more levels for degenerative disc disease (DDD) into 2 groups. Group 1
      would receive tranexamic acid during the surgery while group 2 will receive placebo. Blood
      loss during the surgery and postoperatively (while the patient has a drain) will be monitored
      along with the amount of transfusions needed and the duration of hospital stay.

      The drug or placebo are only given during the surgery. The patient population includes
      elective cases of patient undergoing lumbar spinal fusion of 2 or more levels. Spinal fusions
      are known to be associated with blood loss, especially when the surgeries are long and more
      levels need to be fused.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 2B randomized, single-center, double-blinded, placebo vs treatment clinical trial with 1:1 randomization</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transfusion</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Amount (in cells cubed) of red blood cells (RBC) transfused intraoperatively and up to 7 days post-operatively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Loss</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Amount (in cells cubed) of blood loss intraoperatively and up to 7 days post-operatively</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1:1 randomization, given tranexamic acid during surgery, visual acuity exam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1:1 randomization, given standard of care treatment during surgery, visual acuity exam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Antifibrinolytic Agent</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Visual Acuity Exam</intervention_name>
    <description>Supplemented into standard of care daily neurological exam on day of surgery and day after</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Eye Exam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-80 years

          2. American Spinal Injury Association (ASIA) Impairment Scale anesthesia risk of I to IV

          3. Body Mass Index (BMI) of&lt;35

          4. Patients undergoing 2 or more levels of posterior lumbar interbody fusion for DDD.
             This includes PLIF or TLIF.

          5. Patients have failed conservative management, which include physical therapy (PT) or
             occupational therapy (OT) and/or injections.

        Exclusion Criteria:

          1. ASIA class V

          2. Patient unable to consent

          3. Patient with chronic kidney disease stage III or above: baseline plasma
             creatinine&gt;1.5mg/dL

          4. Patient with known liver failure

          5. Patients on anticoagulation or dual antiplatelets (presence of vascular stents).

          6. Patients with artificial valves.

          7. Patients with allergy to TXA

          8. Patients with platelet count &lt; 150 000,

          9. Patients with PT&lt;60%

         10. Patients with Activated Partial Thromboplastin Time (APPT) &gt;38s

         11. History of stroke or (an) unprovoked thromboembolic event(s).

         12. History of intracranial bleeding,

         13. Pregnancy

         14. known defective color vision

         15. history of venous or arterial thromboembolism or active thromboembolic disease

         16. Patients with severe pulmonary or cardiac disease.

         17. Patients who refuse transfusion of blood products

         18. Patients with chronic anemia with Hg&lt;8

         19. Patients undergoing lumbar fusion for disease other than DDD (neoplasm)

         20. Patients undergoing lumbar fusion by anterior or lateral approach.

         21. Minimally invasive TLIF are excluded.

         22. Emergent cases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Zanaty, M.D&gt;</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eleanor C Ryan</last_name>
    <phone>319-467-5677</phone>
    <email>eleanor-ryan@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mario Zanaty, M.D.</last_name>
    <phone>(319) 356-7643</phone>
    <email>mario-zanaty@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Eleanor C Ryan</last_name>
      <phone>937-570-2541</phone>
      <email>eleanor-ryan@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mario Zanaty, M.D.</last_name>
      <phone>(319) 356-7643</phone>
      <email>mario-zanaty@uiowa.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Mario Zanaty</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Posterior Lumbar Interbody Fusion</keyword>
  <keyword>Transforaminal Lumbar Interbody Fusion</keyword>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Neurosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

